Stock Updates

A look at a High Market Cap Stock: Bristol-Myers Squibb Company, BMY

Bristol-Myers Squibb Company, BMY is in the exchange NYSE and its industry is Drug Manufacturers – Major in the sector of Healthcare. Based in USA, Bristol-Myers Squibb Company, BMY  has a market cap of 96888.53. Since its IPO date on the 6/1/1972, Bristol-Myers Squibb Company, BMY performance year to date is -13.87%. Today Bristol-Myers Squibb Company, BMY has gained 0.73%, with a current price of 59.01.

Ownership of the company is 0.10% for insider ownership while institutional ownership is 74.30%. The management of the company have seen the company have a payout ratio of 87.80%. Return of assets are at 9.00%, with return on investment at 4.60%.

In terms of debt levels and profit levels, Bristol-Myers Squibb Company, BMY is seeing a long-term debt/equity of 0.44. While Total debt/equity is 0.45. With a profit margin of 16.30%, this is combined with a gross margin of 75.70%, and operating margin of 20.80%. Bristol-Myers Squibb Company ability to meet debt levels, with a current ratio of 1.6, while the quick ratio is 1.4.

For the last year Bristol-Myers Squibb Company, BMY has seen a EPS growth of -22.30%. A performance for the year of 3.58%. The 52-week high is -23.48%, and the 52-week low is 7.22%. The average volume for Bristol-Myers Squibb Company, BMY is 4436803.

With a target price of 68.75, can Bristol-Myers Squibb Company, BMY reach this target? Looking at the value indicators of Bristol-Myers Squibb Company, BMY. Bristol-Myers Squibb Company has a P/E of 34.28 and a forward P/E of 19.34. Perhaps the more useful indicator than P/E, is PEG which has a value of 1.75. Bristol-Myers Squibb Company also has a P/S and a P/B of 5.5 and 6.56 respectively. For P/cash, Bristol-Myers Squibb Company has a value of 20.83, while it is *TBA for P/free cash flow.

At the current price of 59.01, Bristol-Myers Squibb Company has a dividend yield of 2.59%. We see a return on equity of 19.60%.

Looking more long-term Bristol-Myers Squibb Company, is projected to get an EPS growth for the next five years of 19.59%. In the short-term an EPS growth of 15.13% in the next year is forecasted. This is after a EPS growth of -22.30% for this year and for the last five years a -12.20% growth has been seen.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Tony Dabbs

Leave a Comment